ALT
Price
$4.24
Change
+$0.06 (+1.44%)
Updated
Jan 15, 04:59 PM (EDT)
Capitalization
436.15M
70 days until earnings call
Intraday BUY SELL Signals
NBY
Price
$12.71
Change
-$0.03 (-0.24%)
Updated
Jan 15, 04:59 PM (EDT)
Capitalization
1.6B
Intraday BUY SELL Signals
Interact to see
Advertisement

ALT vs NBY

Header iconALT vs NBY Comparison
Open Charts ALT vs NBYBanner chart's image
Altimmune
Price$4.24
Change+$0.06 (+1.44%)
Volume$57.16K
Capitalization436.15M
NovaBay Pharmaceuticals
Price$12.71
Change-$0.03 (-0.24%)
Volume$1.2K
Capitalization1.6B
ALT vs NBY Comparison Chart in %
ALT
Daily Signal:
Gain/Loss:
NBY
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ALT vs. NBY commentary
Jan 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a Hold and NBY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 16, 2026
Stock price -- (ALT: $4.18 vs. NBY: $12.73)
Brand notoriety: ALT and NBY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALT: 70% vs. NBY: 54%
Market capitalization -- ALT: $436.15M vs. NBY: $1.6B
ALT [@Biotechnology] is valued at $436.15M. NBY’s [@Biotechnology] market capitalization is $1.6B. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALT’s FA Score shows that 0 FA rating(s) are green whileNBY’s FA Score has 2 green FA rating(s).

  • ALT’s FA Score: 0 green, 5 red.
  • NBY’s FA Score: 2 green, 3 red.
According to our system of comparison, NBY is a better buy in the long-term than ALT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALT’s TA Score shows that 5 TA indicator(s) are bullish while NBY’s TA Score has 3 bullish TA indicator(s).

  • ALT’s TA Score: 5 bullish, 4 bearish.
  • NBY’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, ALT is a better buy in the short-term than NBY.

Price Growth

ALT (@Biotechnology) experienced а -0.24% price change this week, while NBY (@Biotechnology) price change was +19.64% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.44%. For the same industry, the average monthly price growth was +2.31%, and the average quarterly price growth was +42.34%.

Reported Earning Dates

ALT is expected to report earnings on Mar 26, 2026.

Industries' Descriptions

@Biotechnology (-0.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NBY($1.6B) has a higher market cap than ALT($436M). NBY YTD gains are higher at: 125.709 vs. ALT (15.789). NBY has higher annual earnings (EBITDA): -6.59M vs. ALT (-83.72M). ALT has more cash in the bank: 211M vs. NBY (2.31M). NBY has less debt than ALT: NBY (970K) vs ALT (15.9M). NBY has higher revenues than ALT: NBY (10.3M) vs ALT (20K).
ALTNBYALT / NBY
Capitalization436M1.6B27%
EBITDA-83.72M-6.59M1,270%
Gain YTD15.789125.70913%
P/E RatioN/A2.47-
Revenue20K10.3M0%
Total Cash211M2.31M9,138%
Total Debt15.9M970K1,639%
FUNDAMENTALS RATINGS
ALT vs NBY: Fundamental Ratings
ALT
NBY
OUTLOOK RATING
1..100
5930
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
34
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9712
PRICE GROWTH RATING
1..100
6434
P/E GROWTH RATING
1..100
1001
SEASONALITY SCORE
1..100
n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NBY's Valuation (34) in the Biotechnology industry is somewhat better than the same rating for ALT (96) in the Miscellaneous Commercial Services industry. This means that NBY’s stock grew somewhat faster than ALT’s over the last 12 months.

NBY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ALT (100) in the Miscellaneous Commercial Services industry. This means that NBY’s stock grew similarly to ALT’s over the last 12 months.

NBY's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for ALT (97) in the Miscellaneous Commercial Services industry. This means that NBY’s stock grew significantly faster than ALT’s over the last 12 months.

NBY's Price Growth Rating (34) in the Biotechnology industry is in the same range as ALT (64) in the Miscellaneous Commercial Services industry. This means that NBY’s stock grew similarly to ALT’s over the last 12 months.

NBY's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for ALT (100) in the Miscellaneous Commercial Services industry. This means that NBY’s stock grew significantly faster than ALT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALTNBY
RSI
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
N/A
MACD
ODDS (%)
Bullish Trend 2 days ago
76%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
N/A
Bullish Trend 9 days ago
82%
Declines
ODDS (%)
Bearish Trend 7 days ago
86%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
ALT
Daily Signal:
Gain/Loss:
NBY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
COVAX13.470.06
+0.45%
Columbia Sm Cp Val and Inflection A
PVFAX51.160.06
+0.12%
Paradigm Value
NAEFX77.77-0.09
-0.12%
New Alternatives Investor
OGICX41.12-0.06
-0.15%
Invesco Global Opportunities C
LMPLX53.34-0.73
-1.35%
ClearBridge Large Cap Growth R

ALT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALT has been loosely correlated with ACHV. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ALT jumps, then ACHV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALT
1D Price
Change %
ALT100%
+4.24%
ACHV - ALT
47%
Loosely correlated
+1.63%
INDP - ALT
45%
Loosely correlated
+1.31%
KROS - ALT
39%
Loosely correlated
+0.15%
AMRN - ALT
38%
Loosely correlated
-0.99%
RXRX - ALT
35%
Loosely correlated
+3.41%
More

NBY and

Correlation & Price change

A.I.dvisor indicates that over the last year, NBY has been loosely correlated with ATON. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if NBY jumps, then ATON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBY
1D Price
Change %
NBY100%
-2.38%
ATON - NBY
38%
Loosely correlated
-29.47%
NEVPF - NBY
34%
Loosely correlated
N/A
ALT - NBY
30%
Poorly correlated
+4.24%
ORMP - NBY
29%
Poorly correlated
+7.37%
ZNTL - NBY
28%
Poorly correlated
+0.86%
More